ClinicalTrialsFinder

Relapsed or Refractory Aggressive B-cell Lymphoma Clinical Trials in Tianjin

1 recruitingTianjin, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

Relapsed or Refractory Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China25 enrolled1 locationNCT06996132